Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
19:01:22 EDT Thu 27 Mar 2025
Enter Symbol
or Name
USA
CA



Q:MDGL - MADRIGAL PHARMACEUTICALS INC - https://www.madrigalpharma.com.
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
MDGL - Q0.7320.00·353.001.1337.27+3.451.0124.841,5974,116333.82  338.44  331.665377.46  189.0017:39:33Mar 1115 min RT 2¢

Recent Trades - Last 10 of 4116
Time ETExPriceChangeVolume
17:39:33Q326.00-7.822
17:20:37Q326.00-7.822
16:36:56Q337.273.4526
16:24:20Q337.273.4576
16:05:05Q337.273.451
16:01:10Q337.273.45216
16:01:05Q337.273.45274
16:00:58Q338.004.183
16:00:43Q337.273.45234
16:00:06Q337.273.452

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2025-03-11 08:00U:MDGLNews ReleaseMadrigal Appoints Jacqualyn A. Fouse, Ph.D. to Its Board of Directors
2025-02-26 07:00U:MDGLNews ReleaseMadrigal Pharmaceuticals Reports Fourth-Quarter and Full-Year 2024 Financial Results and Announces New Two-Year Data Demonstrating Potential Benefit of Rezdiffra(TM) (resmetirom) in Patients with Compensated MASH Cirrhosis
2025-02-26 06:30U:MDGLNews ReleaseMadrigal Announces New Two-Year Data from the Compensated MASH Cirrhosis Arm of the MAESTRO-NAFLD-1 Trial Demonstrating Potential Benefit of Rezdiffra(TM) (resmetirom) in Patients with Compensated MASH Cirrhosis
2025-02-21 08:00U:MDGLNews ReleaseMadrigal Pharmaceuticals to Participate in the 45th Annual TD Cowen Health Care Conference
2025-02-12 08:00U:MDGLNews ReleaseMadrigal Pharmaceuticals to Release Fourth-Quarter and Full-Year 2024 Financial Results and Host Webcast on February 26, 2025
2025-01-13 06:45U:MDGLNews ReleaseMadrigal Pharmaceuticals Announces Preliminary* Fourth-Quarter and Full-Year 2024 Net Sales, Year-End Cash and Total Patients on Rezdiffra
2025-01-03 08:00U:MDGLNews ReleaseMadrigal Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
2024-11-06 08:00U:MDGLNews ReleaseMadrigal Pharmaceuticals, Inc. Announces Participation at Three Upcoming Investor Conferences
2024-10-31 07:00U:MDGLNews ReleaseMadrigal Pharmaceuticals Reports Third-Quarter 2024 Financial Results and Provides Corporate Updates
2024-10-30 08:00U:MDGLNews ReleaseMadrigal Pharmaceuticals to Present Multiple Rezdiffra(TM) (resmetirom) Abstracts in NASH/MASH at the AASLD Liver Meeting(TM)
2024-10-21 08:00U:MDGLNews ReleaseMadrigal Pharmaceuticals Completes Enrollment of Clinical Outcomes Study of Resmetirom in Patients with Compensated NASH/MASH Cirrhosis
2024-10-18 08:00U:MDGLNews ReleaseMadrigal Pharmaceuticals to Release Third-Quarter 2024 Financial Results and Host Webcast on October 31, 2024
2024-10-02 08:00U:MDGLNews ReleaseMadrigal Pharmaceuticals to Participate in the H.C. Wainwright & Co. 8th Annual MASH Investor Conference
2024-10-01 08:00U:MDGLNews ReleaseMadrigal Pharmaceuticals Appoints Dr. Michael R. Charlton as Senior Vice President, Clinical Development
2024-09-30 08:00U:MDGLNews ReleaseMadrigal Pharmaceuticals Announces Publication of Positive Health-Related Quality of Life Results from the Phase 3 MAESTRO-NASH Trial of Rezdiffra(TM) (resmetirom)
2024-08-26 08:00U:MDGLNews ReleaseMadrigal Pharmaceuticals, Inc. to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
2024-08-07 07:00U:MDGLNews ReleaseMadrigal Pharmaceuticals Reports Second-Quarter 2024 Financial Results and Provides Corporate Updates
2024-08-02 07:00U:MDGLNews ReleaseMadrigal Pharmaceuticals Appoints Shannon Kelley as General Counsel
2024-07-24 08:00U:MDGLNews ReleaseMadrigal Pharmaceuticals to Release Second-Quarter 2024 Financial Results and Host Webcast on August 7, 2024
2024-06-06 08:00U:MDGLNews ReleaseMadrigal Pharmaceuticals Announces New Data from the Phase 3 MAESTRO-NASH Study of Rezdiffra(TM) (resmetirom) Presented at the EASL Congress